Replies to post #58457 on Anavex Life Sciences Corp (AVXL)

[circa1762]

Ah, I see, Heptares partnership, not buyout. Heptares was bought for $400M by Sosei in Feb 2015 but remained a distinct subsidiary of Sosei. Now Heptares/Sosei gets $125M upfront from Allergan just on one drug that somewhat resembles Anavex 2-73, with potential to earn $665M on completion of phase 3 and to earn $2.5B on achieving certain sales targets.

Hmm, let's see, what has happened since Feb 2015 that might make that one Heptares drug suddenly seem worth more than the entire company sold for just one year ago? We know it wasn't safety results from the phase 1 trial of the Heptares drug, so....

I'd say you are very correct that Anavex has the big boys' attention.